BiotechTube

Agalsidase beta + Agalsidase beta

Phase 3Completed
0 watching 0 views this week📈 Rising
76
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Fabry Disease

Conditions

Fabry Disease

Trial Timeline

Sep 1, 2008 → Jun 1, 2015

NCT ID
NCT00701415

About Agalsidase beta + Agalsidase beta

Agalsidase beta + Agalsidase beta is a phase 3 stage product being developed by Sanofi for Fabry Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT00701415. Target conditions include Fabry Disease.

Hype Score Breakdown

Clinical
27
Activity
18
Company
9
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT00701415Phase 3Completed

Competing Products

20 competing products in Fabry Disease

See all competitors
ProductCompanyStageHype Score
LucerastatIdorsiaPhase 3
72
Fabrazyme (agalsidase beta)SanofiPhase 2
51
Venglustat (GZ402671) + PlaceboSanofiPhase 3
76
Fabrazyme (agalsidase beta) + Fabrazyme (agalsidase beta)SanofiPhase 2
51
agalsidase betaSanofiApproved
84
TropicamideSanofiPre-clinical
22
Fabrazyme (agalsidase beta)SanofiApproved
84
agalsidase betaSanofiApproved
84
AGALSIDASE BETA (GZ419828) + Acetaminophen + Diphenhydramine + Dexamethasone + Montelukast + Loratadine + Cetirizine + FexofenadineSanofiApproved
84
Gabapentin + placeboSanofiPhase 2
51
Agalsidase betaSanofiApproved
84
GZ/SAR402671SanofiPhase 2
51
agalsidase beta (GZ419828) + agalsidase alfaSanofiApproved
84
Fabrazyme (agalsidase beta)SanofiPhase 3
76
Venglustat (GZ402671) + Agalsidase alfa + Agalsidase beta (GZ419828) + MigalastatSanofiPhase 3
76
IohexolSanofiPhase 1
32
GZ/SAR402671SanofiPhase 2
51
Fabrazyme (agalsidase beta)SanofiPhase 2
51
Agalsidase betaSanofiApproved
84
Fabrazyme (agalsidase beta) + PlaceboSanofiApproved
84

Other Products from Sanofi

Adacel®Approved
84
LACTIC ACID(ND)Approved
84
DupilumabApproved
84
glatiramer acetateApproved
84
INSULIN GLULISINE + INSULIN GLARGINEApproved
84